Exousia Pro, Inc. Announces Executed LOI for Strategic Acquisition of High-Revenue Telehealth Platform to Accelerate Nutraceutical Commercialization

Rhea-AI Summary

Exousia Pro (OTCID:MAJI) executed a Letter of Intent to acquire a high-revenue telehealth platform and will operate it through new subsidiary Exousia Health.

The platform adds ~$80,000 monthly recurring revenue and an exclusive contract to supply testosterone across 1,900 clinics, starting February 2026, modeled to add $2.4 million in annual revenue based on 2,000 daily scripts over a 300-day year. Management projects $3.0 million net income for fiscal 2026 and intends to use the channel to sell Maxasome™ and future diagnostics.

Positive

• Adds ~$80,000 monthly recurring revenue
• Exclusive contract covering 1,900 clinics begins February 2026
• Projected $2.4M incremental annual revenue from the contract
• Company projects $3.0M net income for fiscal 2026
• Immediate direct sales channel for Maxasome™ and diagnostics

Negative

• Revenue projections depend on fulfilling 2,000 daily scripts
• Exclusive contract value assumes a 300-day service year
• Projected net income is management forecast, not guaranteed

News Market Reaction – MAJI

-5.77%

1 alert

-5.77% News Effect

On the day this news was published, MAJI declined 5.77%, reflecting a notable negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Monthly recurring revenue: $80,000 Clinic network: 1,900 clinics Contract annual revenue: $2.4 million +3 more

6 metrics

Monthly recurring revenue $80,000 Existing telehealth platform revenue at acquisition

Clinic network 1,900 clinics Exclusive Testosterone supply contract coverage

Contract annual revenue $2.4 million Projected from exclusive Testosterone contract starting February 2026

Daily scripts 2,000 scripts Projected daily prescriptions under Testosterone contract

Service year length 300 days Assumed service year for revenue projection

Projected net income $3.0 million Exousia Health projected net income for fiscal year 2026

Market Reality Check

Price: $0.0410 Vol: Volume 342,202 is slightl...

normal vol

$0.0410 Last Close

Volume Volume 342,202 is slightly above the 304,851 20-day average (relative volume 1.12). normal

Technical Price at 0.052 is trading below the 0.12 200-day moving average.

Peers on Argus

Peers show mixed to negative moves, with CVSI down 3.72% and RVVTF down 28% whil...

Peers show mixed to negative moves, with CVSI down 3.72% and RVVTF down 28% while several others are flat, suggesting MAJI’s -16.13% move appears more stock-specific than a broad sector trend.

Historical Context

5 past events · Latest: Dec 05 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Dec 05	Product launch	Positive	+0.2%	Launch of Maxasome™ exosomal nutraceutical targeting longevity and wellness market.
Dec 02	Licensing deal	Positive	+33.3%	Exclusive worldwide license for exosomal cancer diagnostic and therapy platforms.
Nov 17	Strategic acquisition	Positive	-44.2%	All-stock deal for controlling stake in LMMY and exosome tech licensing structure.
Nov 04	Technical milestone	Positive	+3.5%	Successful loading of CBD into milk-derived exosomes using proprietary protocol.
Oct 28	Regulatory designation	Positive	+9.1%	FDA Orphan Drug Designation for exosome-based treatment for malignant glioma.

Pattern Detected

Most prior positive news (product launches, licensing, regulatory milestones) has aligned with positive price reactions, with one notable divergence on a complex all-stock acquisition.

Recent Company History

This announcement continues a busy period for Exousia Pro. In late October 2025, the company received FDA Orphan Drug Designation for its glioblastoma program, followed by a cannabinoid delivery breakthrough on November 4 and an all-stock controlling-stake acquisition of LMMY on November 17. Early December brought an exclusive cancer-diagnostic license and the launch of the Maxasome™ exosomal nutraceutical. Today’s telehealth-focused acquisition LOI deepens the Exousia Health strategy to commercialize these assets through integrated care channels.

Market Pulse Summary

The stock moved -5.8% in the session following this news. A negative reaction despite the revenue pr...

Analysis

The stock moved -5.8% in the session following this news. A negative reaction despite the revenue projections could fit the prior pattern where an all-stock acquisition on November 17, 2025 saw a sharp decline, even with seemingly positive strategic rationale. While this LOI outlines $80,000 in current monthly revenue and a projected $2.4 million annual contract, investors may focus on execution risk, integration complexity, or balance-sheet concerns. Historical volatility around corporate actions suggests that sentiment can diverge from the company’s optimistic financial projections.

Key Terms

telehealth, subsidiary, nutraceutical, exosome-based, +1 more

5 terms

telehealth technical

"it has executed a Letter of Intent to acquire a high-growth, established telehealth organization."

Telehealth is the delivery of healthcare services and consultations remotely using video calls, phone, text messaging, or connected devices to monitor and transmit medical information. It matters to investors because it can reshape how patients access care, lower costs, and create new revenue streams or risks for healthcare providers, insurers and technology companies—similar to how online banking changed financial services—while also exposing businesses to reimbursement and regulatory shifts.

subsidiary financial

"will operate under Exousia Pro's newly-formed subsidiary, Exousia Health, Inc."

A subsidiary is a company that is controlled or owned by a larger company, known as the parent company. Think of it like a branch or division of a bigger organization; it operates separately but is ultimately guided by the parent. For investors, understanding subsidiaries helps clarify how a larger company is structured and where its resources and risks are concentrated.

nutraceutical medical

"sales channel for its advanced nutraceutical and diagnostic products."

A nutraceutical is a product made from food ingredients that is promoted to provide health benefits beyond basic nutrition — for example vitamins, herbal extracts, fortified foods, and dietary supplements. Investors watch nutraceuticals because they sit between food and medicine: consumer demand, limited regulation, and claims about health effects can drive fast sales and higher margins but also create liability, regulatory risk, and uncertainty about long‑term efficacy, which affect company value.

exosome-based medical

"a clinical-stage biotechnology company focused on proprietary exosome-based delivery systems"

Exosome-based describes therapies, diagnostics or delivery systems that use exosomes—tiny, naturally produced packets cells release—to carry proteins, RNA or drugs to other cells. For investors this signals a platform approach that could enable more precise targeting with fewer side effects than conventional drugs, but it also brings manufacturing, stability and regulatory hurdles that influence development time, cost and commercial risk.

net income financial

"company projecting to achieve a net income of $3.0 million in fiscal year 2026."

Net income is the amount of money a company keeps after paying all its costs, interest, taxes and one-time charges — effectively the company’s profit “left over” at the end of a reporting period. Investors use it like a report card: it shows whether the business is generating real profit, influences earnings per share and dividend potential, and helps determine valuation and long-term financial health.

AI-generated analysis. Not financial advice.

ORLANDO, FL / ACCESS Newswire / December 11, 2025 / Exousia Pro, Inc. (OTCID:MAJI), a clinical-stage biotechnology company focused on proprietary exosome-based delivery systems, is excited to announce that it has executed a Letter of Intent to acquire a high-growth, established telehealth organization. Once acquired the Telehealth Platform will operate under Exousia Pro's newly-formed subsidiary, Exousia Health, Inc.

This strategic transaction is designed to immediately generate substantial revenue, expand Exousia Pro's network, and create an unparalleled, cost-effective sales channel for its advanced nutraceutical and diagnostic products.

Immediate Revenue Impact and Growth Projections

The platform enters the portfolio with a solid financial base of approximately $80,000 in monthly recurring revenue. Furthermore, Exousia Health immediately gains control of a significant, established contract that designates the platform as the exclusive supplier of Testosterone across a robust network of 1,900 clinics. This high-impact agreement is slated to begin in February 2026 and is conservatively projected to add $2.4 million in annual revenue, based on projected fulfillment of 2,000 daily scripts over a 300-day service year.

Overall, the acquisition is expected to position Exousia Health for robust financial performance, with the company projecting to achieve a net income of $3.0 million in fiscal year 2026.

Powerful Synergy: Accelerating Shareholder Value

The primary strategic benefit of this acquisition lies in the ability of Exousia Health to immediately leverage the telehealth group's existing network and large, specialized client base which includes individuals highly invested in wellness, anti-aging, and regenerative treatments.

This established client funnel is perfectly aligned with Exousia Pro's product pipeline, particularly the recently launched Maxasome™ exosomal nutraceutical.

• Cost-Effective Client Acquisition: By utilizing the telehealth platform's existing client relationships, Exousia Health drastically reduces the substantial consumer acquisition costs typically associated with launching a premium nutraceutical line.

• Direct Sales Channel: The platform provides a turn-key mechanism for cross-selling high-margin products, including Maxasome™ and future offerings like the NANOG DNA cancer screening test. This integration is projected to elevate the subsidiary's monthly revenue, significantly enhancing the overall top-line growth.

"We are incredibly excited about this acquisition, as it represent the foundational first step in driving sustained, significant revenue through Exousia Health," stated Matt Dwyer, President of Exousia Pro, Inc. "As we strategically expand Exousia Health with our cancer screening test and innovative nutritional supplements, this transaction creates crucial synergy, allowing us to offer these proprietary products directly to a highly engaged client base. This integration will not only dramatically increase our overall revenue but will also enable us to achieve superior net profit margins."

About Exousia Pro, Inc.

Exousia Pro, Inc. (OTCID: MAJI), through its subsidiaries, is dedicated to developing and commercializing advanced exosome-based technologies. Our mission spans clinical-stage therapeutics, next-generation cancer diagnostics, and high-efficacy nutraceuticals, all centered on proprietary exosomal science and delivery system.

SAFE HARBOR

Forward-looking statements in this release are made under the "safe harbor" provision of the Private Securities Litigation Reform Act of 1995. Exousia Pro, Inc.'s forward-looking statements do not guarantee future performance. This news release includes forward-looking statements concerning the parties' future level of business. These statements are necessarily subject to risk and uncertainty. Actual results could differ materially from those projected in these forward-looking statements due to certain risk factors that could cause results to differ materially from estimated results. Management cautions that all statements as to future results of operations are necessarily subject to risks, uncertainties, and events that may be beyond the control of Exousia Pro, Inc., and no assurance can be given that such results will be achieved. Potential risks and uncertainties include, but are not limited to, the ability to procure, appropriately price, retain, and complete projects and changes in products and competition.

CONTACT:

Exousia Pro, Inc.
www.Exousiapro.com
X: @Exousia_Pro

Investor Relations
ir@exousiapro.com

SOURCE: Exousia Pro, Inc.

View the original press release on ACCESS Newswire

FAQ

What did Exousia Pro (MAJI) announce on December 11, 2025 about an acquisition?

Exousia Pro executed an LOI to acquire a telehealth platform to operate under Exousia Health and expand direct sales channels.

How much monthly recurring revenue does the telehealth platform add to MAJI?

The platform contributes approximately $80,000 in monthly recurring revenue.

What revenue impact does the MAJI announcement forecast from the 1,900-clinic contract?

Management projects the exclusive contract to add about $2.4 million annually based on 2,000 daily scripts over 300 days.

When does the exclusive testosterone supply contract for MAJI's new subsidiary start?

The contract is slated to begin in February 2026.

What net income does Exousia Pro (MAJI) project for fiscal 2026 after the acquisition?

The company projects a net income of $3.0 million for fiscal year 2026.

How will the telehealth acquisition affect MAJI's product commercialization?

The platform creates a turn-key direct-sales channel to cross-sell Maxasome™ and future diagnostics to an established client base.